Mind Medicine (MindMed) Inc at Canaccord Genuity Growth Conference Transcript
(audio in progress) Barrow, the CEO of Mind Medicine. Mind Medicine or MindMed for short is a neuro-pharmaceutical company developing psychedelic-inspired medicines. Its clinical programs include the study of an ibogaine derivative for opioid withdrawal and addiction and the study of LSD for ADHD and anxiety, as well as pain.
Mr. Barrow joined MindMed as Chief Development Officer earlier this -- earlier last year. And few months later, he was promoted to CEO -- so very quickly -- briefly served as Director of Drug Development and Discovery at Usona Institute. And this is a not-for-profit. He was actually one of the early incumbents in the psychedelic research space. They were looking at psilocybin for depression, similar to many other companies in the space.
Now, Robert, I would like to invite you to join me up here on the podium to tell our investors a little bit about MindMed. I would like to remind everyone, please hold your questions for the end. We will give you five minutes to ask questions after the presentation.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
